Effect of prostaglandin E1 on renin and aldosterone in hypertensive patients. 1979

M Yoshimura, and H Takahashi, and R Takashina, and Y Kajita, and T Miyazaki, and T Hachiya, and H Ijichi, and Y Ochi

The effect of prostaglandin E1 (PGE1) on plasma renin activity (PRA) and plasma aldosterone concentration (PAC) was studied in the hypertensive subjects treated with or without 75 mg indomethacin or 60 mg propranolol for a week. Subsequent to the treatment with indomethacin for a week, PRA and PAC levels were decreased as compared to the control, without changes in the blood pressure and heart rate. During the infusion of PGE1, the blood pressure was decreased and the pulse rate was increased. PRA and PAC levels were also elevated. These changes of parameters were not different between the control and the indomethacin-treated subjects. PRA and PAC were suppressed after the treatment with propranolol. With the infusion of PGE1, the level of PRA was not significantly elevated, while, PAC was significantly increased by the infusion of 100 ng/Kg/min of PGE1. During the infusion of PGE1, the blood pressure was decreased while the pulse rate was increased in the subjects treated with propranolol. However, the elevation of the pulse rate was less remarkable than the control. These data indicate that PGE1 have important roles in the regulation of the release of renin and aldosterone. These findings also suggest that PGE1 may act to stimulate the secretion of aldosterone in man.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007213 Indomethacin A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Amuno,Indocid,Indocin,Indomet 140,Indometacin,Indomethacin Hydrochloride,Metindol,Osmosin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011433 Propranolol A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. Dexpropranolol,AY-20694,Anaprilin,Anapriline,Avlocardyl,Betadren,Dociton,Inderal,Obsidan,Obzidan,Propanolol,Propranolol Hydrochloride,Rexigen,AY 20694,AY20694,Hydrochloride, Propranolol
D011458 Prostaglandins E (11 alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid (PGE(1)); (5Z,11 alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid (PGE(2)); and (5Z,11 alpha,13E,15S,17Z)-11,15-dihydroxy-9-oxoprosta-5,13,17-trien-1-oic acid (PGE(3)). Three of the six naturally occurring prostaglandins. They are considered primary in that no one is derived from another in living organisms. Originally isolated from sheep seminal fluid and vesicles, they are found in many organs and tissues and play a major role in mediating various physiological activities. PGE
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

M Yoshimura, and H Takahashi, and R Takashina, and Y Kajita, and T Miyazaki, and T Hachiya, and H Ijichi, and Y Ochi
January 1993, The Journal of international medical research,
M Yoshimura, and H Takahashi, and R Takashina, and Y Kajita, and T Miyazaki, and T Hachiya, and H Ijichi, and Y Ochi
January 1980, International journal of clinical pharmacology, therapy, and toxicology,
M Yoshimura, and H Takahashi, and R Takashina, and Y Kajita, and T Miyazaki, and T Hachiya, and H Ijichi, and Y Ochi
April 1971, The American journal of physiology,
M Yoshimura, and H Takahashi, and R Takashina, and Y Kajita, and T Miyazaki, and T Hachiya, and H Ijichi, and Y Ochi
July 1976, Clinical science and molecular medicine,
M Yoshimura, and H Takahashi, and R Takashina, and Y Kajita, and T Miyazaki, and T Hachiya, and H Ijichi, and Y Ochi
May 2016, Orvosi hetilap,
M Yoshimura, and H Takahashi, and R Takashina, and Y Kajita, and T Miyazaki, and T Hachiya, and H Ijichi, and Y Ochi
January 1986, Advances in experimental medicine and biology,
M Yoshimura, and H Takahashi, and R Takashina, and Y Kajita, and T Miyazaki, and T Hachiya, and H Ijichi, and Y Ochi
October 1976, Circulation research,
M Yoshimura, and H Takahashi, and R Takashina, and Y Kajita, and T Miyazaki, and T Hachiya, and H Ijichi, and Y Ochi
January 1978, Bollettino della Societa italiana di cardiologia,
M Yoshimura, and H Takahashi, and R Takashina, and Y Kajita, and T Miyazaki, and T Hachiya, and H Ijichi, and Y Ochi
August 1975, The Tohoku journal of experimental medicine,
M Yoshimura, and H Takahashi, and R Takashina, and Y Kajita, and T Miyazaki, and T Hachiya, and H Ijichi, and Y Ochi
May 1982, The Tohoku journal of experimental medicine,
Copied contents to your clipboard!